Eslicarbazepine acetate (BIA 2-093); Placebo
Проводит БИАЛ-Портела и K°, С.А.
Страница компанииEffects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01527513/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 6–16 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 123 чел. во всех странах исследования.
- Центров в реестре: 9 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (05.2013) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 16 · невключение: 25
Критерии включения
- At visit 1 (screening), patient must be/have:
- written informed consent by parent or legal guardian and, where applicable, the patient;
- age 6 to 16 years, inclusive;
- a documented diagnosis of epilepsy for at least 12 months prior to screening;
- at least 2 partial onset seizures during the 4 weeks prior to screening despite treatment with 1 to 2 AEDs in a stable dose regimen;
- an Intelligence Quotient (IQ) of at least 70;
- current treatment with 1 to 2 AEDs (except oxcarbazepine, benzodiazepines other than clobazam and vagus nerve stimulation (VNS));
- excepting epilepsy, patient is judged to be in general good health based on medical history, physical examination and clinical laboratory tests;
- in the opinion of the investigator, able to complete the Cognitive Drug Research (CDR) test battery;
- in case of a girl of childbearing potential, patient presents a serum B-human chorionic gonadotropin (B hCG) test consistent with a non gravid state and agrees to remain abstinent or use reliable contraception (if used, hormonal contraception must be combined with a barrier method) starting at screening and continuing until at least the post-study visit (PSV).
- At visit 2 (randomisation), patient must be/have:
- at least 2 partial-onset seizures during the 4 week baseline period prior to randomisation (documented in a diary);
- in case of a girl of childbearing potential, patient presents a urine B-hCG test consistent with a non-gravid state;
- stable dose regimen of concomitant AEDs during the 4 week baseline period;
- diaries satisfactorily completed by the patient or his/her caregiver during the baseline period;
- satisfactory compliance with the study requirements during the baseline period.
Критерии невключения
- At visit 1 (screening), patients must not be/have:
- only simple partial seizures with no motor symptomatology;
- primarily generalised seizures;
- known rapidly progressive neurological disorders (progressive brain disease, epilepsy secondary to progressive cerebral lesion);
- occurrence of seizures too close to count accurately;
- history of status epilepticus or cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months prior to screening; seizures of non-epileptic origin;
- Lennox-Gastaut syndrome;
- West syndrome;
- major psychiatric disorders;
- seizures of psychogenic origin within the last 2 years;
- history of schizophrenia or suicide attempt;
- history of attention deficit disorder or other diseases adversely affecting cognitive abilities;
- currently treated with oxcarbazepine, benzodiazepines other than clobazam (on a routine or chronic basis) and/or VNS;
- known hypersensitivity to carboxamide derivatives (oxcarbazepine or carbamazepine);
- uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological or oncology disorder;
- second or third degree atrioventricular blockade;
- relevant clinical laboratory abnormalities;
- estimated creatinine clearance (CLCR) <60 mL/min;
- pregnancy or nursing;
- treatment with eslicarbazepine acetate in any previous study;
- participation in other drug clinical trial within the last 2 months;
- not ensured capability to perform the trial;
- any other condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol.
- At visit 2 (randomisation), patients must not be / have:
- any condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol.
Источник: ClinicalTrials.gov, NCT01527513 · запись обновлена в реестре 24 октября 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 2
- Change From Baseline in Power of Attention Score to the End of the Double Blind (DB) Period — Visit 1 (-4 weeks for training), Visit 2 (Day 1), Visit 5 (6 weeks), Visit 7 (12 weeks) or at early discontinuation visit (EDV)
Цель исследования
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.
Где проходит
9 центров в 6 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01527513 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.